Skip to main content

. 1995 Mar;4(1):52–54. doi: 10.1136/qshc.4.1.52

The ideal: enemy of the useful?

T A Sheldon ¹, A F Long ¹, N Freemantle ¹, F Song ¹

PMCID: PMC1055268 PMID: 10142038

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Freemantle N., Maynard A. Something rotten in the state of clinical and economic evaluations? Health Econ. 1994 Mar-Apr;3(2):63–67. doi: 10.1002/hec.4730030202. [DOI] [PubMed] [Google Scholar]
Robinson R. Cost-benefit analysis. BMJ. 1993 Oct 9;307(6909):924–926. doi: 10.1136/bmj.307.6909.924. [DOI] [PMC free article] [PubMed] [Google Scholar]
Song F., Freemantle N., Sheldon T. A., House A., Watson P., Long A., Mason J. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ. 1993 Mar 13;306(6879):683–687. doi: 10.1136/bmj.306.6879.683. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES